Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Increasing Trends of Cancer Diagnoses in People with Multiple Sclerosis
Multiple Sclerosis
P4 - Poster Session 4 (5:30 PM-6:30 PM)
9-019
To investigate cancer risk in multiple sclerosis (MS) patients.
Studies assessing the prevalence and incidence of cancer in MS patients have shown controversial results.
Nested case-control study using data collected between 01/01/1987 and 28/02/2016 from the United Kingdom (UK) Clinical Practice Research Datalink. The occurrence of cancer after a first MS code (index date) was assessed in 10,204 MS patients and 39,448 controls matched by sex, age, general practitioner and year of registration. Cancer risk in MS vs controls was estimated using multivariate Cox-regression models.
MS patients had a median (IQR) age of 47 (39-57) years, and 71.6% were females. Median follow-up after index date was 5.6 (2.4-9.9) years. Cancer was reported in 433 (4.4%) MS patients and 2,014 (5.3%) controls. Cancer risk was associated with gender (HR for female=0.88, 95%CI=0.81-0.96, p=0.004), age at index date (HR=1.06, 95%CI=1.06-1.07, p<0.001), and index year (HR =1.01, 95%CI=1.00-1.02, p=0.016), but not with MS status (HR=0.95, 95%CI=0.86-1.05, p=0.323). However, a significant interaction between MS status and index year was found (HR 1.02, 95%CI=1.00-1.04, p=0.022). Accordingly, risk of cancer was positively associated with index year among MS patients (HR=1.03, 95%CI=1.01-1.05; p=0.010), but not controls (HR=1.01, 95%CI=1.00-1.02; p=0.144). The most frequently observed cancers among MS patients were breast cancer (1.83% of female patients), non-melanoma skin cancer (1.14%) and prostate cancer (0.9%). However, no increased risk of any specific cancer type was present among MS patients as compared to controls.
In this large UK based nested case-control study, overall cancer risk was similar in MS patients and matched controls. However, the frequency of cancer diagnoses has increased over time among MS patients but not in controls.
Authors/Disclosures
Claudio Gobbi, MD (Ospedale Regionale Lugano)
PRESENTER 		Dr. Gobbi has nothing to disclose.
Giulio Disanto, MD, PhD (Neurologia, Ospedale Civico) The institution of Dr. Disanto has received research support from Swiss MS Sociery.
No disclosure on file
No disclosure on file
Sreeram Ramagopalan No disclosure on file
Chiara Zecca, MD (Ente ospedaliero cantonale) Prof. Zecca has nothing to disclose.